Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$7.56 USD
-0.30 (-3.82%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.54 -0.02 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Bicycle Therapeutics PLC Sponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BCYC 7.56 -0.30(-3.82%)
Will BCYC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
Other News for BCYC
Bicycle Therapeutics (BCYC) Target Price Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics (BCYC) Price Target Reduced by RBC Capital | BCYC Stock News
Bicycle Therapeutics price target lowered by $7 at RBC Capital, here's why
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCYC ...